Published by Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA shall not be responsible for any consequences resulting from the use of this English version.

## **Revision of PRECAUTIONS**

## Posaconazole

May 8, 2024

## Therapeutic category

Antibiotic preparations acting mainly on mold

<u>(</u>)

## Non-proprietary name

Posaconazole

**Safety measure** PRECAUTIONS should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>

Revised language is underlined.

Current	Revision
2. CONTRAINDICATIONS (This drug is contraindicated to the	2. CONTRAINDICATIONS (This drug is contraindicated to the
following patients.)	following patients.)
Patients receiving the following drugs: Ergotamine	Patients receiving the following drugs: Ergotamine
tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine,	tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine,
methylergometrine, ergometrine, simvastatin, atorvastatin,	methylergometrine, ergometrine, simvastatin, atorvastatin,
pimozide, quinidine, venetoclax [during its dose escalation phase	pimozide, quinidine, venetoclax [during its dose escalation phase
for relapsed or refractory chronic lymphocytic leukemia (including	for relapsed or refractory chronic lymphocytic leukemia (including
small lymphocytic lymphoma)], suvorexant, lurasidone	small lymphocytic lymphoma)], suvorexant, lurasidone
hydrochloride, blonanserin, triazolam	hydrochloride, blonanserin, triazolam <u>, rivaroxaban</u>
10. INTERACTIONS	10. INTERACTIONS
10.1 Contraindications for Co-administration (Do not co-administer with	10.1 Contraindications for Co-administration (Do not co-administer with
the following.)	the following.)
(N/A)	Drugs Signs, symptoms, and Mechanism/risk factors treatment
	Rivaroxaban The anticoagulant The plasma concentration of
	effect of rivaroxaban rivaroxaban is expected to may be enhanced, and rise due to the inhibition of
	a risk of haemorrhage CYP3A4, as well as the
	may be increased. possible inhibition of P-gp, by
	co-administration with
	posaconazole.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>